GSK inks $1 billion cancer drug deal

Share this article:

GlaxoSmithKline said it is acquiring the rights to Synta Pharmaceuticals' skin cancer drug STA-4783 in a deal worth up to $1.1 billion.

The drug uses a new mechanism of action to kill malignant cells.

STA-4783 is administered as an injection is about to begin Phase III trials for melanoma involving 600 patients.
The companies will share costs for development in other indications and will jointly sell the drug in the US, with Synta receiving a tiered profit share, the companies said.

FDA approves generic versions of Novartis epilepsy drug

The FDA has approved the first generic versions of Novartis' epilepsy treatment Trileptal (oxcarbazepine).

Roxane Laboratories, Sun Pharmaceuticals and Glenmark Pharmaceuticals won approval to sell versions of oxcarbazepine in three strengths – 150 mg 300 mg and 600 mg.

US sales of Trileptal were $549 million in 2006.

Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.